• Explore /
  • Poster
  • / Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing intensified androgen deprivation therapy (ADT).

Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing intensified androgen deprivation therapy (ADT).

Abstract Poster

Authors

null

Umang Swami

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

Umang Swami , Beverly Chigarira , Nicolas Sayegh , Taylor Ryan McFarland , Nishita Tripathi , Roberto Nussenzveig , Adam Kessel , Clara Tandar , Divyam Goel , Jackson Cheney , Blake Nordblad , Vinay Mathew Thomas , Deepika Sirohi , Benjamin L. Maughan , Neeraj Agarwal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 133)

DOI

10.1200/JCO.2022.40.6_suppl.133

Abstract #

133

Poster Bd #

P7

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Genitourinary Cancers Symposium

Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS)

Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS)

First Author: Benjamin L. Maughan

First Author: Jesse Meir Zaretsky

First Author: Syed Arsalan Ahmed Naqvi

First Author: Kim N. Chi